Chemical proteomics-based drug design: Target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4571-4580

  Ge, Xia ^a   Wakim, Bassam ^b   Sem, Daniel S ^a  

^a Marquette University   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL; DIHYDRODIPICOLINATE REDUCTASE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RHODANINE; SCAFFOLD PROTEIN;

ARTICLE; BACTERIAL CELL; BINDING AFFINITY; CELL TRANSPORT; CELL WALL; DRUG BINDING; DRUG DESIGN; DRUG TARGETING; HUMAN; HUMAN TISSUE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEOMICS;

CATECHOLS; DRUG DESIGN; ESCHERICHIA COLI; MASS SPECTROMETRY; MOLECULAR STRUCTURE; NADP; PROTEINS; PROTEOMICS; RHODANINE; SEPHAROSE;

EID: 49449109858     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8002284     Document Type: Article

References (58)

1. Fitzgerald, G. A. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat. Rev. Drug Discovery 2005, 4, 815-818.
2. Tolliday, N.; Clemons, P. A.; Ferraiolo, P.; Koehler, A. N.; Lewis, T. A.; Li, X.; Schreiber, S. L.; Gerhard, D. S.; Eliasof, S. Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics. Cancer Res. 2006, 66, 8935-8942.
3. Strausberg, R. L.; Schreiber, S. L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 2003, 300, 294-295.
4. Krishnamurty, R.; Maly, D. J. Chemical genomic and proteomic methods for determining kinase inhibitor selectivity. Comb. Chem. High Throughput Screening 2007, 10, 652-666.
5. Daub, H.; Godl, K.; Brehmer, D.; Klebl, B.; Muller, G. Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev. Technol. 2004, 2, 215-224.
6. Peters, E. C.; Gray, N. S. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem. Biol. 2007, 2, 661-664.
7. Argyrou, A.; Jin, L.; Siconilfi.Baez, L.; Angeletti, R. H.; Blanchard, J. S. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 2006, 45, 13947-13953.
8. Schalon, C.; Surgand, J. S.; Kellenberger, E.; Rognan, D. A simple and fuzzy method to align and compare draggable ligand-binding sites. Proteins, in press.
9. Hajduk, P. J.; Huth, J. R.; Tse, C. Predicting protein draggability. Drug Discovery Today 2005, 10, 1675-1682.
10. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged structures: applications in drug discovery. Comb. Chem. High Throughput Screening 2004, 7, 473-494.
11. Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini-Rev. Med. Chem. 2007, 7, 1108-1119.
12. Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 2006, 13, 65-85.
13. Muller, G. Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today 2003, 8, 681-691.
14. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
15. Brustle, M.; Beck, B.; Schindler, T.; King, W.; Mitchell, T.; Clark, T. Descriptors, physical properties, and drug-likeness. J. Med. Chem. 2002, 45, 3345-3355.
16. Peters, U.; Cherian, J.; Kim, J. H.; Kwok, B. H.; Kapoor, T. M. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat. Chem. Biol. 2006, 2, 618-626.
17. Smith, A. B., 3rd; Favor, D. A.; Sprengeler, P. A.; Guzman, M. C.; Carroll, P. J.; Furst, G. T.; Hirschmann, R. Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffold. Bioorg. Med. Chem. 1999, 7, 9-22.
18. Amano, M.; Koh, Y.; Das, D.; Li, J.; Leschenko, S.; Wang, Y. F.; Boross, P. I.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. A novel bis- tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-Pl-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 2007, 51, 2143-2155.
19. Guo, T.; Hobbs, D. W. Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. Assay Drug Dev. Technol. 2003, 1, 579-592.
20. Sasse, B. C.; Mach, U. R.; Leppaenen, J.; Calmels, T.; Stark, H. Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands. Bioorg. Med. Chem. 2007, 15, 7258-7273.
21. Sem, D. S.; Bertolaet, B.; Baker, B.; Chang, E.; Costache, A. D.; Coutts, S.; Dong, Q.; Hansen, M.; Hong, V.; Huang, X.; Jack, R. M.; Kho, R.; Lang, H.; Ma, C. T.; Meininger, D.; Pellecchia, M.; Pierre, F.; Villar, H.; Yu, L. Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem. Biol. 2004, 11, 185-194.
22. Kho, R.; Newman, J. V.; Jack, R. M.; Villar, H. O.; Hansen, M. R. Genome-wide profile of oxidoreductases in viruses, prokaryotes, and eukaryotes. J. Proteome Res. 2003, 2, 626-632.
23. Kho, R.; Baker, B. L.; Newman, J. V.; Jack, R. M.; Sem, D. S.; Villar, H. O.; Hansen, M. R. A path from primary protein sequence to ligand recognition. Proteins 2003, 50, 589-599.
24. Godl, K.; Wissing, J.; Kurtenbach, A.; Habenberger, P.; Blencke, S.; Gutbrod, H.; Salassidis, K.; Stein-Gerlach, M.; Missio, A.; Cotten, M.; Daub, H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15434-15439.
25. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25, 1035-1044.
26. Poupaert, J.; Carato, P.; Colacino, E.; Yous, S. 2(3H)- Benzoxazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes. Curr. Med. Chem. 2005, 12, 877-885.
27. Matsuoka, K.; Sakamoto, N.; Akanuma, Y.; Hotta, N.; Shichiri, M.; Toyota, T.; Oka, Y.; Kawamori, R.; Shigeta, Y. ADCT Study Group. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complication Trial. Diabetes Res. Clin. Pract. 2007, 77, S263-268.
28. Hotta, N.; Akanuma, Y.; Kawamori, R.; Matsuoka, K.; Oka, Y.; Shichiri, M.; Toyota, T.; Nakashima, M.; Yoshimura, I.; Sakamoto, N.; Shigeta, Y. ADCT Study Group. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care 2006, 29, 1538-1544.
29. Bolton, J. L.; Pisha, E.; Shen, L.; Krol, E. S.; Iverson, S. L.; Huang, Z.; van.Breemen, R. B.; Pezzuto, J. M. The reactivity of o-quinones which do not isomerize to quinone methides correlates with alkylcatechol-induced toxicity in human melanoma cells. Chem. Biol. Interact. 1997, 106, 133-148.
30. Hutzler, J. M.; Melton, R. J.; Rumsey, J. M.; Thompson, D. C.; Rock, D. A.; Wienkers, L. C. Chem. Res. Toxicol., in press.
31. Barry, S.; O'Carra, P. Affinity chromatography of nicotinamide - adenine dinucleotide-linked dehydrogenases on immobilized derivatives of the dinucleotide. Biochem. J. 1973, 135, 595-607.
32. Morelli, A.; Benatti, U. Simple chemical synthesis of a specific effector for the affinity chromatography of nicotinamide adenine dinucleotide phosphate-dependent dehydrogenases. Ital. J. Biochem. 1974, 23, 279-291.
33. Trayer, I. P.; Trayer, H. R. Affinity chromatography of nicotinamide nucleotide-dependent dehydrogenases on immobilized nucleotide derivatives. Biochem. J. 1974, 141, 775-787.
34. Ng, E.; Schriemer, D. C. Emerging challenges in ligand discovery: new opportunities for chromatographic assay. Expert Rev. Proteomics 2005, 2, 891-900.
35. Bertrand, R.; Derancourt, J.; Kassab, R. Fluorescence characterization of structural transitions at the strong actin binding motif in skeletal myosin affinity labeled at cysteine 540 with novel spectroscopic cysteaminyl mixed disulfides. Biochemistry 2000, 39, 14626-14637.
36. Scapin, G.; Reddy, S. G.; Zheng, R.; Blanchard, J. S. Three-dimensional structure of Escherichia coli dihydrodipicolinate reductase in complex with NADH and the inhibitor 2,6-pyridinedicarboxylate. Biochemistry 1997, 36, 15081-15088.
37. Ge, X.; Sem, D. S. Affinity-based chemical proteomic probe for dehydrogenases: fluorescence and visible binding assays in gels. Anal. Biochem. 2007, 370, 171-179.
38. Barglow, K. T.; Cravatt, B. F. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 2007, 4, 822-827.
39. Evans, M. J.; Saghatelian, A.; Sorensen, E. J.; Cravatt, B. F. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 2005, 23, 1303-1307.
40. Dye, C.; Scheele, S.; Dolin, P.; Pathania, V.; Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA, J. Am. Med. Assoc. 1999, 282, 677-686.
41. Okada, M.; Kobayashi, K. Recent progress in mycobacteriology. Kekkaku 2007, 82, 783-799.
42. Hori, T.; Ishijima, J.; Yokomizo, T.; Ago, H.; Shimizu, T.; Miyano, M. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. J. Biochem. 2006, 140, 457-466.
43. Clish, C. B.; Sun, Y. P.; Serhan, C. N. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. Biochem. Biophys. Res. Commun. 2001, 288, 868-874.
44. Mills, P. B.; Strays, E.; Jakobs, C.; Plecko, B.; Baxter, P.; Baumgartner, M.; Willemsen, M. A.; Omran, H.; Tacke, U.; Uhlenberg, B.; Weschke, B.; Clayton, P. T. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat. Med. 2006, 12, 307-309.
45. Bok, L. A.; Strays, E.; Willemsen, M. A.; Been, J. V.; Jakobs, C. Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch Dis. Child. 2007, 92, 687-689.
46. Salomons, G. S.; Bok, L. A.; Strays, E. A.; Pope, L. L.; Darmin, P. S.; Mills, P. B.; Clayton, P. T.; Willemsen, M. A.; Jakobs, C. An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1). Ann. Neurol. 2007, 62, 414-418.
47. Eirich, L. D.; Vogels, G. D.; Wolfe, R. S. Distribution of coenzyme F420 and properties of its hvdrolytic fragments. J. Bacteriol. 1979, 140, 20-27.
48. Eirich, L. D.; Vogels, G. D.; Wolfe, R. S. Proposed structure for coenzyme F420 from Methanobacterium. Biochemistry 1978, 17, 4583-4593.
49. Purwantini, E.; Daniels, L. Molecular analysis of the gene encoding F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis. J. Bacteriol. 1998, 180, 2212-2219.
50. Salvetti, S.; Celandroni, F.; Ghelardi, E.; Baggiani, A.; Senesi, S. Rapid determination of vitamin B2 secretion by bacteria growing on solid media. J. Appl. Microbiol. 2003, 95, 1255-1260.
51. Messinger, J.; Hirvela, L.; Husen, B.; Kangas, L.; Koskimies, P.; Pentikainen, O.; Saarenketo, P.; Thole, H. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 2006, 248, 192-198.
52. Rizner, T. L.; Zakelj-Mavric, M. Characterization of fungal 17beta-hydroxysteroid dehydrogenases. Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. 2000, 127, 53-63.
53. Purkayastha, A.; McCue, L. A.; McDonough, K. A. Identification of a Mycobacterium tuberculosis putative classical nitroreductase gene whose expression is coregulated with that of the acr gene within macrophages, in standing versus shaking cultures, and under low oxygen conditions. Infect. Immun. 2002, 70, 1518-1529.
54. Srivastava, V.; Rouanet, C.; Srivastava, R.; Ramalingam, B.; Locht, C.; Srivastava, B. S. Macrophage-specific Mycobacterium tuberculosis genes: identification by green fluorescent protein and kanamycin resistance selection. Microbiology 2007, 153, 659-666.
55. Vanin, E. F.; Ji, T. H. Synthesis and application of cleavable photoactivable heterobifunctional reagents. Biochemistry 1981, 20, 6754-6760.
56. Witzemann, V.; Muchmore, D.; Raftery, M. A. Affinity-directed cross-linking of membrane-bound acetylcholine receptor polypeptides with photolabile alpha-bungarotoxin derivatives. Biochemistry 1979, 18, 5511-5518.
57. Waugh, S. M.; DiBella, E. E.; Pilch, P. F. Isolation of a proteolytically derived domain of the insulin receptor containing the major site of cross-linking/binding. Biochemistry 1989, 28, 3448-3455.
58. Reddy, S. G.; Sacchettini, J. C.; Blanchard, J. S. Expression, purification, and characterization of Escherichia coli dihydrodipicolinate reductase. Biochemistry 1995, 34, 3492-3501.